Menu Close

< Return to Evidence

Bibliography

Our bibliography includes peer-reviewed publications that were authored by Consortium researchers (highlighted in bold).

  1. Algarin AB, Plazarte GN, Sovich KR, Seeger SD, Li Y, Cohen RA, Striley CW, Goldberger BA, Wang Y, Somboonwit C, Ibañez GE, Spencer EC, Cook RL Marijuana Use and Health Outcomes in Persons Living With HIV: Protocol for the Marijuana Associated Planning and Long-term Effects (MAPLE) Longitudinal Cohort Study JMIR Res Protoc 2022;11(8):e37153 doi: 10.2196/37153 PMID: 36040775 PMCID: 9472048.
  2. Alipour Haris G, Sarayani A, Winterstein AG. Letter by Alipour Haris et al Regarding Article, “Marijuana Use Among Young Adults (18-44 Years of Age) and Risk of Stroke: A Behavioral Risk Factor Surveillance System Survey Analysis”. Stroke. 2020 May;51(5): e91. DOI: 10.1161/STROKEAHA.120.029273 . Epub 2020 Apr 7. PMID: 32252600.
  3. Bilbrey JA, Ortiz YT, Felix JS, McMahon LR, Wilkerson JL. Evaluation of the terpenes β-caryophyllene, α-terpineol, and γ-terpinene in the mouse chronic constriction injury model of neuropathic pain: possible cannabinoid receptor involvement. Psychopharmacology (Berl). 2022 May;239(5):1475-1486. doi: 10.1007/s00213-021-06031-2 . Epub 2021 Nov 30. PMID: 34846548. 
  4. Blanton HL, Barnes RC, McHann MC, Bilbrey JA, Wilkerson JL, Guindon J. Sex differences and the endocannabinoid system in pain. Pharmacol Biochem Behav. 2021 Mar; 202:173107. doi: 10.1016/j.pbb.2021.173107 . Epub 2021 Jan 12. PMID: 33444598; PMCID: PMC8216879. 
  5. Brown JD, Costales B, van Boemmel-Wegmann S, Goodin AJ, Segal R, Winterstein AG. Characteristics of Older Adults Who Were Early Adopters of Medical Cannabis in the Florida Medical Marijuana Use Registry. J Clin Med. 2020 Apr 18;9(4):1166. DOI: 10.3390/jcm9041166  PMID: 32325769; PMCID: PMC7230351
  6. Brown JD, Goodin AJ.High risk of bias in medical cannabis and cannabinoid clinical trials dictates the need for cautious interpretation. Med Cannabis Cannabinoids. 2021; 4:63-66. DOI: 10.1159/000514732
  7. Brown JD, Goodin AJ. The prevalence of drivers under the influence of medical cannabis must be considered within proper context. Res Social Adm Pharm. 2019 Nov;15(11):1372-1373. DOI: 10.1016/j.sapharm.2019.01.015  Epub 2019 Jan 28. PMID: 30709730.
  8. Brown JD, Goodin AJ. Will Cannabis or Cannabinoids Protect You from SARS-CoV-2 Infection or Treat COVID-19? Med Cannabis Cannabinoids 2022;5:1-4 https://doi.org/10.1159/000522472
  9. Brown JD, Rivera KJ, Crespo-Hernandez LY, Doenges MR, Auchey I, Pharm T and AJ Goodin. Natural and Synthetic Cannabinoids: Pharmacology, Uses, and Adverse Drug Events. J Clin Pharmacol. 2021; Aug; 61 Suppl 2:S37-S52. https://doi.org/10.1002/jcph.1871 PMID: 34396558.
  10. Brown JD, Winterstein AG. Potential Adverse Drug Events and Drug-Drug Interactions with Medical and Consumer Cannabidiol (CBD) Use. J Clin Med. 2019 Jul 8;8(7):989. DOI: 10.3390/jcm8070989 PMID: 31288397; PMCID: PMC6678684  
  11. Brown JD. Potential Adverse Drug Events with Tetrahydrocannabinol (THC) Due to Drug-Drug Interactions. J Clin Med. 2020 Mar 27; 9(4):919. doi: 10.3390/jcm9040919 . PMID: 32230864; PMCID: PMC7231229.
  12. Costales B, Babalonis S, Brown JD, Goodin, AJ. Cannabis effects on driving performance: clinical considerations. Med Cannabis Cannabinoids. 2023; 6:8-14. doi:https://doi.org/10.1159/000528714 
  13. Costales B, van Boemmel-Wegmann S, Winterstein A, Segal R. Clinical Conditions and Prescription Drug Utilization among Early Medical Marijuana Registrants in Florida. J Psychoactive Drugs. 2021 Jan 4:1-10. DOI: 10.1080/02791072.2020.1864069  Epub ahead of print. PMID: 33393877.DOI: 10.1159/000530251
  14. Boullosa CC, Vaddiparti K, Lopez-Quintero C, Varma DS, Cook RL. Clinical Decision Making by Medical Marijuana Physicians in Florida: A Qualitative Assessment. Subst Use Misuse. 2022;57(14):2042-2052. doi: 0.1080/10826084.2022.2129995 . Epub 2022 Oct 28. PMID: 36305815. 
  15. Eeswara A, Pacheco-Spiewak A, Jergova S, Sagen J. Combined non-psychoactive Cannabis components cannabidiol and β-caryophyllene reduce chronic pain via CB1 interaction in a rat spinal cord injury model. PLoS One. 2023 Mar 13;18(3):e0282920. doi: 10.1371/journal.pone.0282920 . PMID: 36913400; PMCID: PMC10010563. 
  16. Goodin A, J, Wilson D, L, Cook R, L, Wang Y, Brown J, Winterstein A, G: Proceedings of the 2021 Cannabis Clinical Outcomes Research Conference. Med Cannabis Cannabinoids 2021. https://doi.org/10.1159/000519037
  17. Goodin AJ, Crum J, Fadool DA, Konin JG, Paikoff S, Sachdeva MS, Singla D, Stiffin R, Vidot DC, Villalba K, Jyot J, Winterstein AG. Abstracts for the 2023 Cannabis Clinical Outcomes Research Conference (CCORC), on behalf of the Scientific Program Committee. Med Cannabis Cannabinoids 20 December 2023; 6 (1): 102–124. https://doi.org/10.1159/000534044 
  18. Goodin AJ, Tran PT, McKee S, Sajdeya R, Jyot J, Cook RL, Wang Y, Winterstein AG. Proceedings of the 2023 Cannabis Clinical Outcomes Research Conference. Med Cannabis Cannabinoids. 2023 Sep 29;6(1):97-101. doi: 10.1159/000533943 . PMID: 37900895; PMCID: PMC10601943. 
  19. Goodin AJ, Winterstein AG, Cook R, Wang Y and JD Brown. Introducing Commentary Series: “Evidence in Context.” Med Cannabis Cannabinoids 2021; 4:61-62. DOI: 10.1159/000512684
  20. Huffstetler CM, Cochran B, May CA, Maykut N, Silver CR, Cedeno C, Franck E, Cox A, Fadool DA. Single cannabidiol administration affects anxiety-, obsessive compulsive-, object memory-, and attention-like behaviors in mice in a sex and concentration dependent manner. Pharmacol Biochem Behav. 2023 Jan; 222:173498. doi: 10.1016/j.pbb.2022.173498 . Epub 2022 Nov 29. PMID: 36455670. 
  21. Jean-Jacques J, Cook R, Winterstein AG, Goodin A, Brown JD, Jugl S, Wang Y. Priorities for Medical Marijuana Research from the Perspective of Physicians, Dispensary Owners/Staff, and Patients: A Survey Study. Med Cannabis Cannabinoids. 2021 Aug 2;4(2):107-113. doi: 10.1159/000518105 . PMID: 35224430; PMCID: PMC8832249. 
  22. Jugl S, Goodin AJ, Brown JD. Climbing the Evidence Pyramid: Dosing Considerations for Medical Cannabis in the Management of Chronic Pain. Med Cannabis Cannabinoids. 2023 Apr 26;6(1):41-45. doi: 10.1159/000530251. PMCID: PMC10134049
  23. Jugl S, Okpeku A, Costales B, Morris E, J, Alipour-Haris G, Hincapie-Castillo J, M, Stetten N, E, Sajdeya R, Keshwani S, Joseph V, Zhang Y, Shen Y, Adkins L, Winterstein A, G, Goodin A: A Mapping Literature Review of Medical Cannabis Clinical Outcomes and Quality of Evidence in Approved Conditions in the USA from 2016 to 2019. Med Cannabis Cannabinoids 2021; 4:21-42. doi: 10.1159/000515069
  24. Jugl S, Sajdeya R, Morris E, J, Goodin A, J, Brown J, D: Much Ado about Dosing: The Needs and Challenges of Defining a Standardized Cannabis Unit. Med Cannabis Cannabinoids 2021. doi: 10.1159/000517154
  25. Kalvala AK, Bagde A, Arthur P, Kulkarni T, Bhattacharya S, Surapaneni S, Patel NK, Nimma R, Gebeyehu A, Kommineni N, Meckes DG Jr, Sun L, Banjara B, Mosley-Kellum K, Dinh TC, Singh M. Cannabidiol-Loaded Extracellular Vesicles from Human Umbilical Cord Mesenchymal Stem Cells Alleviate Paclitaxel-Induced Peripheral Neuropathy. Pharmaceutics. 2023 Feb 7;15(2):554. doi: 10.3390/pharmaceutics15020554 Erratum in: Pharmaceutics. 2023 Aug 25;15(9): PMID: 36839877; PMCID: PMC9964872. 
  26. Kalvala AK, Nimma R, Bagde A, Surapaneni SK, Patel N, Arthur P, Sun L, Singh R, Kommineni N, Nathani A, Li Y, Singh M. The role of Cannabidiol and tetrahydrocannabivarin to overcome doxorubicin resistance in MDA-MB-231 xenografts in athymic nude mice. Biochimie. 2022 Dec 17;208:19-30. doi: 10.1016/j.biochi.2022.12.008 Epub ahead of print. PMID: 36535544. 
  27. Kinnunen K, Robayo LE, Cherup NP, Frank SI, Widerström-Noga E. A preliminary study evaluating self-reported effects of cannabis and cannabinoids on neuropathic pain and pain medication use in people with spinal cord injury. Front Pain Res (Lausanne). 2023 Dec 21;4:1297223. doi: 10.3389/fpain.2023.1297223. PMID: 38188193; PMCID: PMC10767995. 
  28. Kumar Kalvala A, Bagde A, Arthur P, Kumar Surapaneni S, Ramesh N, Nathani A, Singh M. Role of Cannabidiol and Tetrahydrocannabivarin on Paclitaxel-induced neuropathic pain in rodents. Int Immunopharmacol. 2022 Jun; 107:108693. doi: 10.1016/j.intimp.2022.108693 . Epub 2022 Mar 15. PMID: 35303507. 
  29. Lorenzo, E, McClean, C, Ford, JA. Young Adult Medical Cannabis Patients in Florida: Gender Differences in Characteristics of use, Experiences at Dispensaries, and Association With Health-Related Problems. J Drug Issues, 2023.  0(0). https://doi.org/10.1177/00220426231189486 
  30. Marini S, Huber A, Cash MN, Salemi M, Cook RL, Borsa P, Mavian CN. Oral Cannabidiol Treatment Is Associated with an Anti-Inflammatory Gene Expression Signature in Myeloid Cells of People Living with HIV. Cannabis Cannabinoid Res. 2024 Jan 22. doi: 10.1089/can.2023.0139 . Epub ahead of print. PMID: 38252549. 
  31. Markowitz JS, De Faria L, Zhang Q, Melchert PW, Frye RF, Klee BO, Qian Y. The Influence of Cannabidiol on the Pharmacokinetics of Methylphenidate in Healthy Subjects. Med Cannabis Cannabinoids. 2022 Nov 4;5(1):199-206. doi: 10.1159/000527189 . PMID: 36467779; PMCID: PMC9710314. 
  32. McMahon AN, Varma DS, Fechtel H, Sibille K, Li Z, Cook RL, Wang Y. Perceived effectiveness of medical cannabis among adults with chronic pain: Findings from interview data in a three-month pilot study. Cannabis. 2023 Jul 5;6(2):62-75. doi: 10.26828/cannabis/2023/000149 . PMID: 37484052. 
  33. Ortiz, YT, McMahon, LR, & Wilkerson, JL. Medicinal Cannabis and Central Nervous System Disorders. Front Pharmacol. 2022 Apr 21;13:881810. https://doi.org/10.3389/fphar.2022.881810 PMID: 35529444; PMCID: PMC9070567. 
  34. Parisi CE, Wang Y, Varma DS, Vaddiparti K, Ibañez GE, Cruz Carrillo L, Cook RL. Changes in frequency of cannabis use among people with HIV during the COVID-19 pandemic: a multi-methods study to explore the underlying reasons for change. Am J Drug Alcohol Abuse. 2023 Jul 4;49(4):470-480. doi: 10.1080/00952990.2023.2176234 . Epub 2023 Mar 10. PMID: 36898081. 
  35. Patel N, Kommineni N, Surapaneni SK, Kalvala A, Yaun X, Gebeyehu A, Arthur P, Duke LC, York SB, Bagde A, Meckes DG Jr, Singh M. Cannabidiol loaded extracellular vesicles sensitize triple-negative breast cancer to doxorubicin in both in-vitro and in vivo models. Int J Pharm. 2021 Sep 25; 607:120943. doi: 10.1016/j.ijpharm.2021.120943 . Epub 2021 Jul 27. PMID: 34324983; PMCID: PMC8528640. 
  36. Rosenthal M., Pipitone N. Demographics, Perceptions, and Use of Medical Marijuana among Patients in Florida. Med Cannabis Cannabinoids 2021; 4:13-20. DOI 10.1159/000512342 
  37. Roussos-Ross K, Dukharan V, Goodin AJ. Is In-Utero Marijuana Exposure Associated with Childhood Developmental Delay? [20K], Obstetrics & Gynecology: May 2020 – Volume 135 – Issue – p 118S-119S DOI: 10.1097/01.AOG.0000664476.72398.7c
  38. Sagen J, Konin J, Paikoff S, Ford J, Newman D, Jyot J, Goodin AJ. Abstracts of the 2022 Cannabis Clinical Outcomes Research Conference (CCORC), on behalf of the Scientific Program Committee. Med Cannabis Cannabinoids2022; 5:142-158. https://doi.org/10.1159/000527081
  39. Sajdeya R, Brown JD, Goodin AJ: Perinatal Cannabis Exposures and Autism Spectrum Disorders. Med Cannabis Cannabinoids 2021, 4:67-71.  DOI: 10.1159/000515871
  40. Sajdeya R, Cook RL. Need to Improve Dose Measurements in Studies of Marijuana Use for Pain. J Acquir Immune Defic Syndr. 2020 Mar 1; 83(3):e23. DOI 10.1097/QAI.0000000000002238 PMID: 32032280.
  41. Sajdeya R, Fechtel HJ, Spandau G, Goodin AJ, Brown JD, Jugl S, Smolinski NE, Winterstein AG, Cook RL, Wang Y. Protocol of a Combined Cohort and Cross-Sectional Study of Persons Receiving Medical Cannabis in Florida, USA: The Medical Marijuana and Me (M3) Study. Med Cannabis Cannabinoids. 2023 May 9;6(1):46-57. doi: 10.1159/000530052  PMID: 37261066; PMCID: PMC10228286.
  42. Sajdeya R, Goodin AJ, Tighe PJ. Cannabis use assessment and documentation in healthcare: Priorities for closing the gap. Prev Med. 2021 Sep 8:106798. doi: 10.1016/j.ypmed.2021.106798  Epub ahead of print. PMID: 34506820.
  43. Sajdeya R, Joseph V, Stetten N, Ibañez G, Wang Y, Powell L, Somboonwit C, Corsi K, Cook R. Reasons for Marijuana Use and Its Perceived Effectiveness in Therapeutic and Recreational Marijuana Users Among People Living with HIV in Florida. Cannabis. 2021, Volume 4 (1). DOI: 10.26828/cannabis/2021.01.002 
  44. Sajdeya R, Jugl S, Cook R, Brown J, D, Goodin A: Clinical Considerations for Cannabis Use and Cardiovascular Health. Med Cannabis Cannabinoids 2022;5:120-127. https://doi.org/10.1159/000526731
  45. Sajdeya R, Mardini MT, Tighe PJ, Ison RL, Bai C, Jugl S, Hanzhi G, Zandbiglari K, Adiba FI, Winterstein AG, Pearson TA, Cook RL, Rouhizadeh M. Developing and validating a natural language processing algorithm to extract preoperative cannabis use status documentation from unstructured narrative clinical notes. J Am Med Inform Assoc. 2023 May 13:ocad080. doi: 10.1093/jamia/ocad080  Epub ahead of print. PMID: 37178155.
  46. Sajdeya R, Shavers A, Jean-Jacques J, Costales B, Jugl S, Crump C, Wang Y, Manfio L, Pipitone RN, Rosenthal MS, Winterstein AG, Cook RL. Practice Patterns and Training Needs Among Physicians Certifying Patients for Medical Marijuana in Florida. J Prim Care Community Health. 2021 Jan-Dec; 12: 21501327211042790. doi: 10.1177/21501327211042790. PMID: 34452585; PMCID: PMC8404623.
  47. Smolinski N, E, Sajdeya R, Cook R, Wang Y, Winterstein A, G, Goodin A: Proceedings of the 2022 Cannabis Clinical Outcomes Research Conference. Med Cannabis Cannabinoids 2022;5:138-141. https://doi.org/10.1159/000527080
  48. Sturaro C, Fakhoury B, Targowska-Duda KM, Zribi G, Schoch J, Ruzza C, Calò G, Toll L, Cippitelli A. Preclinical effects of cannabidiol in an experimental model of migraine. Pain. 2023 Nov 1;164(11):2540-2552. doi: 10.1097/j.pain.0000000000002960 . Epub 2023 Jun 9. PMID: 37310430. 
  49. Surapaneni SK, Patel N, Sun L, Kommineni N, Kalvala AK, Gebeyehu A, Arthur P, Duke LC, Nimma R, G Meckes D Jr, Singh M. Anticancer and chemosensitization effects of cannabidiol in 2D and 3D cultures of TNBC: involvement of GADD45α, integrin-α5, -β5, -β1, and autophagy. Drug Deliv Transl Res. 2022 Nov;12(11):2762-2777. doi: 10.1007/s13346-022-01137-2 . Epub 2022 Feb 25. PMID: 35217991; PMCID: PMC9811521. 
  50. Vaddiparti K, Liu Y, Bottari S, Boullosa CC, Zhou Z, Wang Y, Williamson J, Cook RL. Improved Post-Traumatic Stress Disorder Symptoms and Related Sleep Disturbances after Initiation of Medical Marijuana Use: Evidence from a Prospective Single Arm Pilot Study. Med Cannabis Cannabinoids. 2023 Nov 13;6(1):160-169. doi: 10.1159/000534710 . PMID: 37965569; PMCID: PMC10642978. 
  51. Vaddiparti K, Liu Y, Bottari S, Crump C, Zhou Z, Wang Y, Willaimson J, Cook RL. Improved posttraumatic stress disorder symptoms and related sleep disturbances after initiation of medical marijuana use: Evidence from a prospective single arm pilot study. Med Cannabis Cannabinoids. 2023 Nov 13;6(1):160-169. doi: 10.1159/000534710 . PMID: 37965569 
  52. Wang Y, Jean Jacques J, Li Z, Sibille KT, Cook RL. Health Outcomes among Adults Initiating Medical Cannabis for Chronic Pain: A 3-month Prospective Study Incorporating Ecological Momentary Assessment (EMA). Cannabis. 2021 Oct;4(2):69-83. doi: 10.26828/cannabis/2021.02.006  PMID: 34671723; PMCID: PMC8525881
  53. Wang Y, Robinson KR, Fechtel HJ, Hartog A. Medical cannabis use and its impact on health among older adults: Recent research findings and future directions. Current Addiction Reports. 2023. https://link.springer.com/article/10.1007/s40429-023-00519-x  
  54. Wilkerson JL, Alberti LB, Thakur GA, Makriyannis A, Milligan ED. Peripherally administered cannabinoid receptor 2 (CB2R) agonists lose anti-allodynic effects in TRPV1 knockout mice, while intrathecal administration leads to anti-allodynia and reduced GFAP, CCL2 and TRPV1 expression in the dorsal spinal cord and DRG. Brain Res. 2022 Jan 1; 1774:147721. doi: 10.1016/j.brainres.2021.147721 . Epub 2021 Nov 10. PMID: 34774500. 
  55. Wilkerson JL, Bilbrey JA, Felix JS, Makriyannis A, McMahon LR. Untapped endocannabinoid pharmacological targets: Pipe dream or pipeline? Pharmacol Biochem Behav. 2021 Jul; 206:173192. doi: 10.1016/j.pbb.2021.173192 . Epub 2021 Apr 29. PMID: 33932409. 
  56. Wilkerson, JL, Alberti, LB, Thakur, GA, Makriyannis, A, Milligan, ED. Peripherally administered cannabinoid receptor 2 (CB2R) agonists lose anti-allodynic effects in TRPV1 knockout mice, while intrathecal administration leads to anti-allodynia and reduced GFAP, CCL2 and TRPV1 expression in the dorsal spinal cord and DRG. Brain Res. 2022 Jan 1; 1774:147721. doi: 0.1016/j.brainres.2021.147721 Epub 2021 Nov 10. PMID: 34774500. 
  57. Zhang, Q, Melchert, PW, Markowitz, JS. Pharmacokinetic Variability of Oral Cannabidiol and Its Major Metabolites after Short-Term High-Dose Exposure in Healthy Subjects. Med Cannabis Cannabinoids 2024, 7 (1): 1–9. https://doi.org/10.1159/000535726  

Last updated March 11th, 2024